“… 2 These challenges include lifelong treatment exposure, adherence to ART, persistence of immune dysfunction and advent of drug resistance mutations (DRMs). 2 , 3 , 4 , 5 Moreover, despite the benefits of ART, it does not provide a sterilising HIV-1 cure due to the lifelong persistence of infection within sanctuaries. 6 Consequently, virological rebound post treatment cessation/interruption remains a concern largely attributed to the existence of reservoir cells, which constitute the main barrier to achieving HIV-1 functional cure or eradication.…”